

Erratum: Church TJ, Haines ST. Treatment Approaches to Patients With Severe Insulin Resistance. *Clinical Diabetes* 2016;34:97–104 (DOI:10.2337/diaclin.34.2.97)

In the original print version of the article listed above, there was a typographical error in Table 2 on page 103. The weight effects of GLP-

1 receptor agonists should have been depicted as two downward-pointing arrows instead of one upward-pointing arrow.

The corrected table row appears below. The online version of the article was revised on 19 April 2016 to reflect this change.

TABLE 2. Pharmacological Treatment Options in the Setting of Severe Insulin Resistance

Medication Class	A1C Lowering*	Hypo-glycemia Risk	Weight Effect	Ease of Use	Tolerability Issues	Relative Cost†
<i>Treatment options that have been evaluated in patients with severe insulin resistance</i>						
GLP-1 receptor agonists	↓↓	↔	↓↓	Subcutaneous; once daily or once weekly	Nausea, vomiting	\$\$\$

*Additional A1C lowering in previously treated patients; ↓ = 0.5–1%, ↓↓ = 1–1.5%, ↓↓↓ = 1.5–2%.

†Relative cost per 30-day supply; \$ = <\$100, \$\$ = \$100–299, \$\$\$ = \$300–750, \$\$\$\$ = >\$750 based on average wholesale price (54).